Improved cardiometabolic risk factors in Japanese patients with type 2 diabetes treated with ipragliflozin: a pooled analysis of six randomized, placebo-controlled trials

Endocrine Journal
Atsunori KashiwagiYoshinori Kosakai

Abstract

To examine differential improvements among cardiovascular risk factors in response to treatment with ipragliflozin in Japanese type 2 diabetes mellitus (T2DM) patients, we conducted a pooled analysis of six randomized, double-blind trials of Japanese T2DM patients who received ipragliflozin 50 mg/day or placebo and had patient-level data for cardiometabolic risk parameters. Risk factors included glycated hemoglobin (HbA1c), body weight, homeostatic model assessment for insulin resistance and beta-cell function (HOMA-R and HOMA-beta, respectively), systolic blood pressure, fasting serum insulin concentrations, and the concentration of uric acid, lipids, and liver enzymes from baseline to end of treatment (EOT; 12-24 weeks). The primary endpoint of each trial was the change in HbA1c from baseline to EOT. Changes in risk factors from baseline to EOT were compared between ipragliflozin-treated and placebo groups, and between two subgroups (high- and low-risk groups for each parameter). All parameters, except low-density lipoprotein cholesterol (LDL-C) and non high-density lipoprotein cholesterol (non HDL-C), improved significantly in the ipragliflozin group. Subgroup analysis revealed a significantly greater improvement in the high...Continue Reading

References

Mar 5, 2011·Kidney International. Supplement·Masayuki Isaji
May 25, 2011·Endocrine Reviews·Muhammad A Abdul-GhaniRalph A Defronzo
Apr 25, 2012·Current Diabetes Reports·Muhammad A Abdul-GhaniRalph A DeFronzo
Mar 29, 2014·Drugs·Raewyn M Poole, Rosselle T Dungo
Apr 16, 2014·The Lancet. Diabetes & Endocrinology·Hannele Yki-Järvinen
Feb 20, 2012·Journal of Diabetes Investigation·Atsunori KashiwagiUNKNOWN Committee on the Standardization of Diabetes Mellitus‐Related Laboratory Testing of Japan Diabetes Society
Aug 16, 2014·World Journal of Diabetes·Iciar Martín-TimónFrancisco Javier Del Cañizo-Gómez
Jan 21, 2015·Diabetes, Obesity & Metabolism·M J DaviesG Meininger
Jan 27, 2015·Atherosclerosis·Nwe Ni Than, Philip N Newsome
Sep 18, 2015·The New England Journal of Medicine·Bernard ZinmanUNKNOWN EMPA-REG OUTCOME Investigators
Dec 28, 2016·Circulation Journal : Official Journal of the Japanese Circulation Society·Kohei KakuUNKNOWN EMPA-REG OUTCOME® Investigators
Jun 13, 2017·The New England Journal of Medicine·Bruce NealUNKNOWN CANVAS Program Collaborative Group
Jun 16, 2016·Journal of Clinical & Translational Endocrinology·Yukihiro BandoDaisyu Toya

❮ Previous
Next ❯

Citations

Oct 14, 2019·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Atsunori KashiwagiJohn P H Wilding
Oct 28, 2020·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Yuji TezukaAtsunori Kashiwagi
Nov 28, 2020·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Mario Simental-MendíaLuis E Simental-Mendía
Jul 22, 2021·Drug Design, Development and Therapy·Wajd Alkabbani, John-Michael Gamble

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.